On Nov 27, major Wall Street analysts update their ratings for $Poseida Therapeutics (PSTX.US)$, with price targets ranging from $9 to $9.
BTIG analyst Justin Zelin downgrades to a hold rating.
William Blair analyst Sami Corwin downgrades to a hold rating.
Cantor Fitzgerald analyst Jennifer Kim downgrades to a hold rating.
H.C. Wainwright analyst Arthur He CFA downgrades to a hold rating, and adjusts the target price from $20 to $9.
Furthermore, according to the comprehensive report, the opinions of $Poseida Therapeutics (PSTX.US)$'s main analysts recently are as follows:
The firm considers the acquisition terms highly advantageous for both Poseida shareholders and Roche, which involved an agreement for Roche to acquire Poseida for $13 per share, consisting of $9 in cash at closing and up to $4 more through a non-tradeable contingent value right based on achievement of certain milestones.
Here are the latest investment ratings and price targets for $Poseida Therapeutics (PSTX.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
